This last year, new data in structural heart disease gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence. In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The<a href="https://solaci.org/en/2022/01/05/the-most-relevant-of-2021-in-structural-heart-disease/" title="Read more" >...</a>
A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, pharmacology. Follow us to keep up to date. The Most Read Articles of 2021: Pharmacology 01- Swan Ganz Associated with Better Outcomes in Cardiogenic Shock: Is It Back? The Swan<a href="https://solaci.org/en/2021/12/24/the-most-read-articles-of-2021-pharmacology/" title="Read more" >...</a>
A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, peripheral vascular disease. Follow us to keep up to date. Most Read Articles on Coronary Disease 01- Post MI Betablockers for Good? Patients receiving optimal medical treatment after MI<a href="https://solaci.org/en/2021/12/24/the-most-read-articles-of-2021-coronary-disease/" title="Read more" >...</a>
A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, peripheral vascular disease. Follow us to keep up to date. 01- SOLACI PERIPHERAL | 6th Clinical Case: Common, Superficial and Deep Femoral Artery Recanalization Dr. Ana Paula Mollón (Arg.)<a href="https://solaci.org/en/2021/12/17/the-most-read-articles-of-2021-peripheral-vascular-disease/" title="Read more" >...</a>
01- Management of Abdominal Aortic Aneurysms in 2021 Abdominal aortic aneurysms (AAA) are those of >3 cm aortic diameter. They run the risk of rupture and ensuing death by bleeding. In consequence, they are treated to repair the aneurysm before it ruptures. Read more HERE 02- Ten Commandments for 2021 Guidelines on Valvular Heart Disease Since<a href="https://solaci.org/en/2021/12/06/novembers-most-read-studies-in-interventional-cardiology-in-solaci-org/" title="Read more" >...</a>
Research on short-term dual antiplatelet therapy (DAPT) is still controversial. These discussions, however, seem to lead to the consensus that beyond the “category” of bleeding or ischemic risk, what is most important is a decision tailored to the patient being treated. DAPT duration should be individual, instead of standardized by a risk score. In the<a href="https://solaci.org/en/2021/11/12/tct-2021-stopdapt-2-and-master-dapt-the-conversation-continues-from-esc-to-tct-2/" title="Read more" >...</a>
Research on short-term dual antiplatelet therapy (DAPT) is still controversial. These discussions, however, seem to lead to the consensus that beyond the “category” of bleeding or ischemic risk, what is most important is a decision tailored to the patient being treated. DAPT duration should be individual, instead of standardized by a risk score. In the<a href="https://solaci.org/en/2021/11/12/tct-2021-stopdapt-2-and-master-dapt-the-conversation-continues-from-esc-to-tct/" title="Read more" >...</a>
One-month dual antiplatelet therapy (DAPT) in patients undergoing acute coronary syndrome (ACS) did not reach the safety and efficacy results observed in the general population of the original trial STOPDAPT-2. The STOPDAPT-2 ACS compared one-month DAPT followed by clopidogrel monotherapy for one year vs. one-year DAPT after PCI. Initially, the study enrolled mostly stable patients<a href="https://solaci.org/en/2021/10/07/stopdapt-2-acs-one-month-dapt-not-enough-in-acute-patients/" title="Read more" >...</a>
01- Best Revascularization Strategy in Patients with Left Ventricular Deterioration Multivessel disease associated to ventricular function deterioration is challenging in terms of risk, when choosing a revascularization strategy. Read also HERE 02- SOLACI Renewed Authorities During the SOLACI-CACI 2021 Congress After a massive event attended by thousands of people, the Latin American Society of Interventional Cardiology renewed its authorities for<a href="https://solaci.org/en/2021/09/10/the-most-read-articles-in-august-in-interventional-cardiology/" title="Read more" >...</a>
The predecessor of this research—RIPCORD, published in 2014—showed that using fractional flow reserve (FFR) changes the treatment strategy in about 25% of patients. That marked the rise of FFR. In fact, the DEFER, FAME, and FAME 2 studies offered results consistent with the original RIPCORD. In this research, authors tested the hypothesis of systematic use of<a href="https://solaci.org/en/2021/09/01/esc-2021-ripcord-2-routine-ffr-evaluation-of-all-epicardial-vessels-during-angiography/" title="Read more" >...</a>